Antibiotic
Pfizer introduces Spectramast LC (ceftiofur hydrochloride), an intramammary infusion indicated for the treatment of mastitis caused by Gram-negative and Gram-positive bacteria.
Pfizer introduces Spectramast LC (ceftiofur hydrochloride), an intramammary infusion indicated for the treatment of mastitis caused by Gram-negative and Gram-positive bacteria.
The product shows efficacy against Escherichia coli, coagulase-negative staphylococci and Streptococcus dysgalactiae.
"We're excited to bring a new product to a market that hasn't seen an innovative, new mastitis treatment in more than 10 years," says Austin Belschner, DVM, MS, manager of dairy veterinary operations for Pfizer Animal Health.
Spectramast LC has a zero-day, pre-slaughter meat withdrawal, which is the shortest withhold time of any available mastitis treatment, allowing greater flexibility and more management options.
Once-a-day dosing and a 72-hour milk withhold time round out the product's benefits, the company says.
The product is sold in 10-mL disposable syringes that contain 125-mg of ceftiofur.
The product can be stored at a controlled room temperature.
For fastest response, visit
